Individualized Drug Dosing using RBF-Galerkin Method: Case of Anemia Management in Chronic Kidney Disease

Erythropoietin (EPO) is a glycoprotein hormone produced by kidney promoting the formation of red blood cells (RBCs) in bone marrow. Decreased EPO production in Chronic Kidney Disease (CKD) results in anemia, a condition which mainly affects the physical component of health-related quality of life (QoL), but is also associated with increased risk of cardiovascular events, and even mortality [1]. Discovery of exogenous recombinant human EPO in the late 1980s has revolutionized the treatment of CKD-related anemia [2 –5], which until that point was primarily treated by repeated blood transfusion– a procedure associated with several complications, including increased risk of infections, allergic reactions, and sensitization impeding kidney transplantation [6–8].
Source: Computer Methods and Programs in Biomedicine - Category: Bioinformatics Authors: Source Type: research